Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas: - manufacturing of diagnosis tests for own account; - sale of diagnosis tests supplied by other manufacturers of semi-finished products; - research and development services for third party; - sale of licenses; - sale of biological reagents.

Employees

397

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
26-06-30	€0.9020	-0.22%	1,560
26-06-29	€0.9040	+1.12%	2,600
26-06-26	€0.8940	0.00%	16,560
26-06-25	€0.8940	-4.89%	50,611
26-06-24	€0.9400	+5.62%	99,553

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Real-time Euronext Paris Other stock markets 03:50:16 2026-06-30 am EDT			5-day change	1st Jan Change
0.9020 ^EUR	-0.22%		+1.35%	+51.34%

Jun. 11	Triple update for Biosynex
May. 25	Paris climbs on hopes of Middle East de-escalation

Market Cap	16.66M 19.03M 15.38M 14.36M 27.04M 1.8B 27.66M 185M 71.46M 888M 71.46M 69.9M 3.08B	P/E 2024	-0.43x	P/E 2025	-0.19x
Enterprise Value	69.85M 79.78M 64.49M 60.22M 113M 7.54B 116M 776M 300M 3.72B 300M 293M 12.92B	EV / Sales 2024	0.71x	EV / Sales 2025	0.68x
Free-Float	40.35%	Yield 2024 *	-	Yield 2025	-

Jun. 11	Triple update for Biosynex
May. 25	Paris climbs on hopes of Middle East de-escalation
May. 25	Biosynex announces the divestment of its molecular biology business
May. 24	An undisclosed buyer signed a binding offer to acquire Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
May. 07	Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
May. 06	Biosynex SA Auditor Raises 'Going Concern' Doubt	CI
Apr. 21	Thales, Vivendi, Mercialys, GTT... stocks to watch today in Paris
Apr. 21	Biosynex postpones publication of annual accounts
Mar. 24	Abivax, Ekinops, Sanofi... stocks to watch today in Paris
Mar. 24	Observation period extended for Biosynex
Feb. 06	A Biosynex Subsidiary to Receive $1.8 Million Grant
Feb. 06	Aperam, Société Générale, Stellantis: Key Stocks to Watch Today in Paris
Jan. 23	JCDecaux, Sanofi, Sword Group... Stocks to Watch Today in Paris

24-10-23	BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY	EQ
23-04-27	Biosynex Completes Acquisition of Chembio Diagnostics, Inc.	AQ
23-04-13	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
23-03-15	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
23-01-31	Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement	AQ

Biosynex Stock

Stocks

ALBIO

FR0011005933

Medical Equipment, Supplies & Distribution

Valuation: Biosynex

Chart: Biosynex

Latest news : Biosynex

Press Releases: Biosynex

News in other languages: Biosynex

Quotes and Performance

Course Extremes

Managers and Directors: Biosynex

Latest insider transactions

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

Jun. 13	Agenda des dividendes et des AG France : GTT, Alten et Exail sur les tablettes
Jun. 11	Bourse : J-1 avant SpaceX, Oracle à la peine, contrat pour Airbus
Jun. 11	Une bonne grosse purge avant SpaceX
Jun. 11	Triple actualité pour Biosynex
Jun. 11	BIOSYNEX SA: BIOSYNEX ANNONCE LA REALISATION DEFINITIVE DE LA CESSION DE SON ACTIVITE DE BIOLOGIE MOLECULAIRE

1 day	-0.22%
1 week	+1.35%
Current month	-14.10%
1 month	-11.57%
3 months	+12.75%
6 months	+55.52%
Current year	+51.34%

1 week	0.89	1.07
1 month	0.88	1.07
Current year	0.56	1.57
1 year	0.46	1.57
3 years	0.46	11
5 years	0.46	28.78
10 years	0.46	30.38

Manager	Title	Age	Since
Larry Abensur CEO	Chief Executive Officer	71	2015-06-23
Thierry Paper CTO	Chief Tech/Sci/R&D Officer	63	2014-12-31
Oren Bitton PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Thierry Paper BRD	Director/Board Member	63	2015-06-23
Thomas Lamy BRD	Director/Board Member	-	2015-06-23
Larry Abensur CHM	Chairman	71	2015-06-23

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-02-14	Elie Fraenckel	Buy	Director	2,500	0.0244%
23-02-14	Elie Fraenckel	Buy	Director	2,500	0.0244%
22-02-27	Larry Abensur	Buy	Chief Executive Officer	2,000	0.0180%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSYNEX	-0.22%	+1.35%	-25.45%	-90.59%	19.03M
GUARDANT HEALTH, INC.	+3.03%	+19.34%	+202.28%	+323.64%	20.39B
BIOMÉRIEUX	-0.93%	+3.90%	-41.06%	-28.01%	9.41B
LANTHEUS HOLDINGS, INC.	-0.20%	+3.18%	+34.47%	+32.10%	7.13B
CARIS LIFE SCIENCES, INC.	-0.97%	+5.83%	-31.67%	-	5.18B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+1.44%	+1.18%	-23.20%	-26.72%	4.97B
10X GENOMICS, INC.	+1.09%	+12.78%	+216.71%	-34.48%	4.72B
DIASORIN S.P.A.	-1.03%	+7.32%	-23.86%	-27.48%	4.23B
ANDON HEALTH CO., LTD.	+0.50%	-8.30%	+85.64%	+91.76%	4.11B
AUTOBIO DIAGNOSTICS CO., LTD.	+4.11%	-0.96%	-19.95%	-41.98%	2.51B
Average	+0.67%	+4.77%	+37.39%	+22.03%	6.27B
Weighted average by Cap.	+1.06%	+8.85%	+78.61%	+111.69%

	2024	2025
Net sales	101M 116M 93.39M 87.21M 164M 10.92B 168M 1.12B 434M 5.39B 434M 424M 18.71B	95.19M 109M 87.88M 82.06M 154M 10.28B 158M 1.06B 408M 5.07B 408M 399M 17.61B
Net income	-43.33M -49.49M -40M -37.36M -70.32M -4.68B -71.92M -481M -186M -2.31B -186M -182M -8.01B	-58.22M -66.5M -53.75M -50.19M -94.49M -6.29B -96.64M -647M -250M -3.1B -250M -244M -10.77B
Net Debt	52.94M 60.46M 48.87M 45.63M 85.9M 5.72B 87.86M 588M 227M 2.82B 227M 222M 9.79B	53.19M 60.75M 49.1M 45.85M 86.32M 5.74B 88.28M 591M 228M 2.83B 228M 223M 9.84B